Dr. Landsman's exceptional background as the Assistant Professor of Surgery at Harvard Medical School will further Kent's medical device applications
CALGARY, Nov. 14, 2017 /CNW/ - Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, today announced that Dr. Adam Landsman, DPM, PhD has joined the company as Chief Medical Officer. Dr. Landsman will serve the team with his clinical background and guide the medical uses of Kent's technology.
"Kent's leading edge technology provides physicians and surgeons value based tissue oxygen saturation levels which are key to improved decision making while reducing costs in wound care and surgical healing," said Dr. Adam Landsman, DPM, PhD, Chief of Division of Podiatric Surgery at the Cambridge Health Alliance (Harvard Medical School). "I have had the opportunity to clinically study and research the benefits of Kent's device. Seeing the value and understanding the practical need for Kent's technology in the clinic, I was eager to join the team behind it."
"I am pleased to have Dr. Landsman, a proven leader with extensive research and clinical expertise, join our team at Kent," said Pierre Lemire, CEO of Kent Imaging. "This is an exciting time for Kent Imaging as we welcome Dr. Landsman and launch our FDA cleared KD203 device."
Dr. Landsman is the Assistant Professor of Surgery at Harvard Medical School. Dr. Landsman holds a PhD and MS in Bioengineering from the University of Pennsylvania, DPM in Podiatric Medicine and Surgery from the Temple University, Pennsylvania College of Podiatric Medicine in which he was the first simultaneous dual degree (DPM/PhD) student in the history of podiatric medical education. Dr. Landsman also holds a BS in Chemical Engineering and English Literature from the University of Virginia.
About Kent Imaging Inc.
Kent Imaging Inc., a leading innovator in multispectral oxygenation imaging, designs, manufactures, and markets imaging technology to improve plastic surgery, colorectal surgery, trauma, wound care, limb salvage, podiatry, burns and cardiac specialties. The team at Kent Imaging is committed to improving patient outcomes by delivering innovative and practical solutions for the healthcare industry. Kent Imaging holds multiple patents in medical technology and is currently commercializing the breakthrough multispectral imaging solutions that assesses tissue oxygen saturation. The company is headquartered in Calgary, Alberta, Canada, and has locations in Chicago, Los Angeles, Salt Lake City and Seattle.
Kent's KD203 is U.S. Food and Drug Administration 510(k) cleared, and Health Canada licensed. The device is available for sale in the United States and Canada. Improving on Kent's previous KC103, the handheld Kent KD203 is intended for use by healthcare professionals as a non-invasive tissue oxygenation measurement system that reports oxygen saturation (StO2), relative oxyhemoglobin level (HbO2), and relative deoxyhemoglobin (Hb) level in superficial tissue. Kent's multispectral imaging technology displays two-dimensional color-coded images of tissue oxygenation of the scanned surface and reports multispectral tissue oxygenation measurements for selected tissue regions. Tissue oxygen saturation measurements provide critical information to help physicians determine at risk tissue and guide treatments to optimize patient outcomes.
SOURCE Kent Imaging
For further information: Kent Imaging Inc., Vonda-Lee Sharun - Marketing Manager, firstname.lastname@example.org